Genetically Modified Cell Therapy Puts Lupus Patients in Remission in NHS Trial

1-Minute Brief

This development signals a potential new approach for treating chronic autoimmune diseases by harnessing patients' own immune systems.

Key Facts

• Five lupus patients in England are in remission after receiving genetically modified cell therapy.
• Patients on the trial have not needed medication to manage their condition.
• The therapy works by genetically modifying cells to help the immune system target problem cells.
• Doctors say the CAR T-cell therapy could offer a cure for chronic autoimmune disease.
• The treatment involves modifying T lymphocytes, a type of white blood cell.

What Happened

A pioneering NHS trial in England treated five lupus patients with CAR T-cell therapy, resulting in remission without ongoing medication.

Why It Matters

The results suggest that genetically modifying patients' immune cells may offer a new treatment option for lupus and potentially other autoimmune conditions.

What's Next

Further studies and trials may be conducted to determine the long-term effectiveness and safety of this therapy for a wider group of patients.